IART Stock — Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation (IART)

Updated October 16, 2026.

IART is a Stock. Its deepest 1-year drawdown was 44.8%.

Integra LifeSciences manufactures and sells surgical instruments and specialized medical devices for neurosurgery, neurocritical care, otolaryngology, and wound care applications, operating through its Codman Specialty Surgical and Tissue Technologies segments and distributing its products globally to hospitals, surgery centers, and healthcare providers. The company does not currently have an established distribution program. This stock appeals primarily to healthcare-focused investors seeking exposure to the surgical devices and specialty medical products sector.

IART performance

Returns are updating. IART's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 44.8%.

IART key facts

Asset type

Stock

Asset class

Equity

Inception date

08/16/1995

Distribution frequency

None

Last close

$13.21 (as of 2026-10-16)

Market cap

$1,027,374,804

Average volume

830981.0

Dividend

$6.37

Beta

1.211

Payout ratio

0.0%

Forward P/E

5.9988

EPS

$-0.09

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

IART risks and drawbacks

The deepest 1-year drawdown on record here is 44.8%.

Who may consider IART — and who may not

It is a weaker fit for investors who need monthly cash flow (IART does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on IART

• All tickers starting with I

Tagged: Healthcare.

Frequently asked questions